The Plasma Metabolomic Profile is Differently Associated with Liver Fat, Visceral Adipose Tissue, and Pancreatic Fat

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2020 Oct 30

PMID 33123723

Citations 8

Authors

Lars Lind

Samira Salihovic

Ulf Riserus

Joel Kullberg

Lars Johansson

Hakan Ahlstrom

Jan W Eriksson

Jan Oscarsson

Affiliations

Soon will be listed here.

Abstract

Context: Metabolic differences between ectopic fat depots may provide novel insights to obesity-related diseases.

Objective: To investigate the plasma metabolomic profiles in relation to visceral adipose tissue (VAT) volume and liver and pancreas fat percentages.

Design: Cross-sectional.

Setting: Multicenter at academic research laboratories.

Patients: Magnetic resonance imaging (MRI) was used to assess VAT volume, the percentage of fat in the liver and pancreas (proton density fat fraction [PDFF]) at baseline in 310 individuals with a body mass index ≥ 25 kg/m2 and with serum triglycerides ≥ 1.7 mmol/l and/or type 2 diabetes screened for inclusion in the 2 effect of omega-3 carboxylic acid on liver fat content studies.

Intervention: None.

Main Outcome Measure: Metabolomic profiling with mass spectroscopy enabled the determination of 1063 plasma metabolites.

Results: Thirty metabolites were associated with VAT volume, 31 with liver PDFF, and 2 with pancreas PDFF when adjusting for age, sex, total body fat mass, and fasting glucose. Liver PDFF and VAT shared 4 metabolites, while the 2 metabolites related to pancreas PDFF were unique. The top metabolites associated with liver PDFF were palmitoyl-palmitoleoyl-GPC (16:0/16:1), dihydrosphingomyelin (d18:0/22:0), and betaine. The addition of these metabolites to the Liver Fat Score improved C-statistics significantly (from 0.776 to 0.861, P = 0.0004), regarding discrimination of liver steatosis.

Conclusion: Liver PDFF and VAT adipose tissue shared several metabolic associations, while those were not shared with pancreatic PDFF, indicating partly distinct metabolic profiles associated with different ectopic fat depots. The addition of 3 metabolites to the Liver Fat Score improved the prediction of liver steatosis.

Citing Articles

Plasma Circulating Metabolites Associated With Steatotic Liver Disease and Liver Enzymes: A Multiplatform Population-Based Study.

Abozaid Y, Ayada I, van Kleef L, Goulding N, Williams-Nguyen J, Kaplan R Gastro Hep Adv. 2025; 4(2):100551.

PMID: 39877862 PMC: 11772964. DOI: 10.1016/j.gastha.2024.09.006.

Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community.

Florea V, Gajjar P, Huang S, Tang J, Zhao S, Davenport M Liver Int. 2024; 45(1):e16147.

PMID: 39673712 PMC: 11649011. DOI: 10.1111/liv.16147.

Genotype-based "virtual" metabolomics in a clinical biobank identifies novel metabolite-disease associations.

Bagheri M, Bombin A, Shi M, Murthy V, Shah R, Mosley J Front Genet. 2024; 15:1392622.

PMID: 38812968 PMC: 11133605. DOI: 10.3389/fgene.2024.1392622.

Relationship of Liver Blood Tests and T1 Relaxation Time With Intra-pancreatic Fat Deposition.

Shamaitijiang X, Kimita W, Ko J, Skudder-Hill L, Liu Y, Petrov M J Clin Exp Hepatol. 2024; 14(3):101343.

PMID: 38304879 PMC: 10827601. DOI: 10.1016/j.jceh.2023.101343.

Genotype-based "virtual" metabolomics in a clinical biobank identifies novel metabolite-disease associations.

Bagheri M, Bombin A, Shi M, Murthy V, Shah R, Mosley J Res Sq. 2023; .

PMID: 37790512 PMC: 10543429. DOI: 10.21203/rs.3.rs-3222588/v2.

References

Poirier P, Despres J . Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil. 2003; 23(3):161-9. DOI: 10.1097/00008483-200305000-00001. View

Haufe S, Witt H, Engeli S, Kaminski J, Utz W, Fuhrmann J . Branched-chain and aromatic amino acids, insulin resistance and liver specific ectopic fat storage in overweight to obese subjects. Nutr Metab Cardiovasc Dis. 2016; 26(7):637-642. DOI: 10.1016/j.numecd.2016.03.013. View

Ganna A, Lee D, Ingelsson E, Pawitan Y . Rediscovery rate estimation for assessing the validation of significant findings in high-throughput studies. Brief Bioinform. 2014; 16(4):563-75. DOI: 10.1093/bib/bbu033. View

von Schonfels W, Patsenker E, Fahrner R, Itzel T, Hinrichsen H, Brosch M . Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. Liver Int. 2014; 35(1):207-14. DOI: 10.1111/liv.12476. View

Oscarsson J, Onnerhag K, Riserus U, Sunden M, Johansson L, Jansson P . Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018; 12(6):1390-1403.e4. DOI: 10.1016/j.jacl.2018.08.003. View

Neeland I, Boone S, Mook-Kanamori D, Ayers C, Smit R, Tzoulaki I . Metabolomics Profiling of Visceral Adipose Tissue: Results From MESA and the NEO Study. J Am Heart Assoc. 2019; 8(9):e010810. PMC: 6512086. DOI: 10.1161/JAHA.118.010810. View

Goffredo M, Santoro N, Trico D, Giannini C, DAdamo E, Zhao H . A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. Nutrients. 2017; 9(7). PMC: 5537762. DOI: 10.3390/nu9070642. View

Linge J, Borga M, West J, Tuthill T, Miller M, Dumitriu A . Body Composition Profiling in the UK Biobank Imaging Study. Obesity (Silver Spring). 2018; 26(11):1785-1795. PMC: 6220857. DOI: 10.1002/oby.22210. View

Fabbrini E, Magkos F, Mohammed B, Pietka T, Abumrad N, Patterson B . Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009; 106(36):15430-5. PMC: 2741268. DOI: 10.1073/pnas.0904944106. View

10.

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

11.

Cheng S, Wiklund P, Autio R, Borra R, Ojanen X, Xu L . Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015; 10(10):e0138889. PMC: 4595021. DOI: 10.1371/journal.pone.0138889. View

12.

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson L . Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3):865-72. DOI: 10.1053/j.gastro.2009.06.005. View

13.

Staaf J, Labmayr V, Paulmichl K, Manell H, Cen J, Ciba I . Pancreatic Fat Is Associated With Metabolic Syndrome and Visceral Fat but Not Beta-Cell Function or Body Mass Index in Pediatric Obesity. Pancreas. 2016; 46(3):358-365. PMC: 5312728. DOI: 10.1097/MPA.0000000000000771. View

14.

Evans A, Dehaven C, Barrett T, Mitchell M, Milgram E . Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009; 81(16):6656-67. DOI: 10.1021/ac901536h. View

15.

Baek S, Kim M, Kim M, Kang M, Yoo H, Lee N . Metabolites distinguishing visceral fat obesity and atherogenic traits in individuals with overweight. Obesity (Silver Spring). 2016; 25(2):323-331. DOI: 10.1002/oby.21724. View

16.

Kasumov T, Li L, Li M, Gulshan K, Kirwan J, Liu X . Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One. 2015; 10(5):e0126910. PMC: 4439060. DOI: 10.1371/journal.pone.0126910. View

17.

Bedogni G, Kahn H, Bellentani S, Tiribelli C . A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010; 10:98. PMC: 2940930. DOI: 10.1186/1471-230X-10-98. View

18.

Eriksson J, Lundkvist P, Jansson P, Johansson L, Kvarnstrom M, Moris L . Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018; 61(9):1923-1934. PMC: 6096619. DOI: 10.1007/s00125-018-4675-2. View

19.

OSullivan J, Morningstar J, Yang Q, Zheng B, Gao Y, Jeanfavre S . Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. J Clin Invest. 2017; 127(12):4394-4402. PMC: 5707166. DOI: 10.1172/JCI95995. View

20.

Kaikkonen J, Wurtz P, Suomela E, Lehtovirta M, Kangas A, Jula A . Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study. Hepatology. 2016; 65(2):491-500. PMC: 5299457. DOI: 10.1002/hep.28899. View